<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076111</url>
  </required_header>
  <id_info>
    <org_study_id>BCSCO003</org_study_id>
    <nct_id>NCT04076111</nct_id>
  </id_info>
  <brief_title>Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China</brief_title>
  <official_title>Patterns of Breast Cancer Management and Prognosis of Breast Cancer in Chinaï¼ša Multicenter, Prospective, Real-world Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fengxi Su</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, prospective, e, real-world cohort survey initiated by researchers to
      focus on the patterns of breast cancer management and prognosis of breast cancer in China,
      and to establish the multicenter, prospective breast cancer data platform. A total of 18
      sites in Guangdong and Henan have cooperated to build a cooperative network unit. The sites
      will conduct prospective and standardized records concerning the clinical pathological
      features, treatment and prognosis of the early breast cancer patients who are treated in
      their own site each year, registering in the REDCap system.This real-world cohort study aims
      to provide a representative and reliable survey data of epidemiological characteristics,
      clinical treatment and prognosis of patients with early breast cancer in China and explore
      the establishment of a national multi-center breast cancer data platform model.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 5, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Breast-conserving surgery rate,</measure>
    <time_frame>baseline</time_frame>
    <description>the proportion between breast-conserving surgery and breast mastectomy surgery baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Breast-conserving surgery rate, sentinel lymph node biopsy rate</measure>
    <time_frame>baseline</time_frame>
    <description>the proportion between sentinel lymph node biopsy and axillary lymph node dissection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epidemiological distribution of pathological stage of breast cancer</measure>
    <time_frame>baseline</time_frame>
    <description>the American Joint Committee on Cancer(AJCC) cancer staging system is used to assign stage for breast cancer patients,including primary tumor stage, regional nodes stage and metastasis stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5year</time_frame>
    <description>Disease free survival (DFS), which defined as the time from the diagnosis of breast cancer to the confirmed time of metastatic disease, or death due to any other cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5year</time_frame>
    <description>Overall survival (OS), which defined as the time from the beginning of diagnosis of breast cancer to the death with any causes.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20000</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who had early stage breast cancer and completed breast surgery
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are hospitalized and treated in a collaborative network unit

          -  Agree to enroll in the study and sign the informed consent form

          -  Histological diagnosis of ductal carcinoma in situ or invasive breast cancer

          -  Accept the Surgery-based surgical treatment

          -  Willing to cooperate with follow-up work

        Exclusion Criteria:

          -  Previously Excisional biopsy (including minimally invasive resection) of the patient's
             breast

          -  Previously received neoadjuvant chemotherapy

          -  Imaging or histological evidence of distant metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fengxi Su, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen Menorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiang liu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen Menorial Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Musheng Zeng, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qianjun Chen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guuangdong Province Hospital of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Peng</last_name>
    <phone>8613430344686</phone>
    <email>pengm33@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kai Chen, MD</last_name>
    <phone>8615920164730</phone>
    <email>chenkai23@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Province Hospital of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qianjun Chen, MD</last_name>
      <email>cqj55@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fengxi Su, MD</last_name>
      <phone>+8613902301822</phone>
      <email>fengxisu@vip.163.com</email>
    </contact>
    <contact_backup>
      <last_name>Min Peng</last_name>
      <phone>+8613430344686</phone>
      <email>pengm33@mail.sysu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Erwei Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Musheng Zeng, MD</last_name>
      <email>zengmsh@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital OF Shantou University Medical College</name>
      <address>
        <city>Shantou</city>
        <state>Guangdong</state>
        <zip>515000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guojun Zhang</last_name>
      <email>guoj_zhang@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dechuang Jiao</last_name>
      <email>jiaodechuang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Fengxi Su</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

